title: Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study.
authors.affiliation: Cluj-Napoca, Romania.
authors.forename: Dan
authors.initials: D
authors.lastname: Călugăru
authors.affiliation: Cluj-Napoca, Romania.
authors.forename: Mihai
authors.initials: M
authors.lastname: Călugăru
mesh_terms: D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor